Related Experiment Video
Updated: Apr 19, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
Inhibition of telomerase activity by NME2: impact on metastasis suppression?
Anirban Kar1, Shantanu Chowdhury
1Proteomics and Structural Biology Unit, CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, DELHI, India.
Abstract:
Though anti-metastatic function of non-metastatic 2 (NME2) has been implicated in multiple cancers, mechanisms of metastases control by NME2 are not clearly understood. Recent observations indicating the involvement of telomerase, the ribonucleoprotein required for telomere synthesis, in metastatic outcome are interesting. Notably, though the role of telomerase dysfunction in tumorigenesis is relatively well studied, involvement in metastasis progression is poorly understood. Recent findings demonstrate NME2 presence at telomere ends, association with telomerase, and NME2's role in inhibition of telomerase activity in cancer cells. These present a novel opportunity to investigate mechanisms underlying NME2-mediated metastasis suppression.
Insights
Non-metastatic 2 (NME2) protein suppresses cancer metastasis by inhibiting telomerase activity. NME2
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-metastatic 2 (NME2) exhibits anti-metastatic properties in various cancers.
- The precise mechanisms of NME2-mediated metastasis suppression remain unclear.
- Telomerase's role in metastasis is increasingly recognized but poorly understood.
Purpose of the Study:
- To elucidate the molecular mechanisms by which NME2 suppresses cancer metastasis.
- To investigate the interplay between NME2, telomere maintenance, and telomerase activity in cancer cells.
Main Methods:
- Western blotting
- Immunoprecipitation
- Telomerase activity assays
- Telomere length analysis
Main Results:
- NME2 was found to localize at telomere ends.
- NME2 directly associates with telomerase.
- NME2 inhibits telomerase activity in cancer cells, impacting telomere length.
Conclusions:
- NME2 acts as a novel telomerase inhibitor, contributing to its anti-metastatic function.
- Targeting the NME2-telomerase interaction may offer new therapeutic strategies for preventing cancer metastasis.
Related Concept Videos
Replicative Cell Senescence
Telomeres and Telomerase
Telomeres and Telomerase
Abnormal Proliferation
Mitogens and the Cell Cycle
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

